Gilead: Kite's CAR T-cell Therapy Yescarta Gets Positive Opinion From CHMP In EU

Gilead Sciences Inc. (GILD) announced Friday that its unit Kite's CAR T-cell Therapy Yescarta (axicabtagene ciloleucel) has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP for use in second-line diffuse large B-cell lymphoma and high-grade B-cell lymphoma.

The positive opinion is for the use of Yescarta in adult patients with DLBCL and HGBL that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.

The CHMP's positive opinion is based on the primary results of the landmark Phase 3 ZUMA-7 study, the largest and longest trial of a CAR T-cell therapy versus standard of care (SOC) in second-line LBCL.

The European Commission will review the CHMP opinion, and a final decision on the marketing authorization is expected in the coming months.

If approved, Yescarta will be the first Chimeric Antigen Receptor or CAR T-cell therapy approved for patients in Europe who do not respond to first-line treatment.

Christi Shaw, CEO, Kite, said, "Today's positive CHMP opinion brings us a step closer to utilizing cell therapy earlier in the treatment journey, potentially transforming the standard of care for the most common and aggressive form of non-Hodgkin lymphoma."

ZUMA-7 is an ongoing, randomized, open-label, global, multicenter (US, Australia, Canada, Europe, Israel) Phase 3 study of 359 patients at 77 centers, evaluating the safety and efficacy of a single-infusion of Yescarta versus current SOC for second-line therapy in adult patients with relapsed or refractory LBCL within 12 months of first-line therapy.

Yescarta was first approved in Europe in 2018 and is currently indicated for three types of blood cancer: Diffuse Large B-Cell Lymphoma (DLBCL); Primary Mediastinal Large B-Cell Lymphoma (PMBCL); and Follicular Lymphoma (FL).

For More Such Health News, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
American Honda Motor Co, Inc. has recalled about 2,900 units of 2022 model year Honda TRX90X All-Terrain Vehicles (ATVs) sold in the United States for possible crash and injury hazard, according to a statement issued by the U.S. Consumer Product Safety Commission or CPSC. The Laundress, a unit of Conopco Inc. d/b/a Unilever, is recalling around 8 million laundry and household cleaning products citing risk of exposure to bacteria, U.S. Consumer Product Safety Commission. The recall involves Laundress laundry detergent, fabric conditioner and other cleaning products. Tesla Inc. has delivered its first Semi, a heavy-duty electric truck, to its customer PepsiCo Inc. during an event at its Nevada Gigafactory. The delivery of 500-mile fully electric Semi truck comes five years after the launch of the truck's prototype in 2017. During Thursday night's Semi Delivery Event at Tesla's Sparks, Nevada factory, CEO Elon Musk, with Dan Priestly, ...
Follow RTT